Category Archives: Generic drug

Japan’s attempt to get in stricter patent protection into free trade agreement raises concern

Source: Times of India 2 Sep 2014 NEW DELHI: Even as the Prime Minister’s visit to Japan generates much excitement, there is concern among those working for improving access to medicines regarding Japan’s attempt to get in stricter patent protection … Continue reading

Posted in access to medicines, ASEAN, FTAs, Generic drug, Indian Patent Law, Intellectual Property, IP Rights, Regional Comprehensive Economic Partnership, TRIPS plus | Leave a comment

MSF cautions India on IP inclusion in RCEP talks

Source:Livemint August 26,2014 Mumbai: Medecins Sans Frontieres (MSF), or Doctors Without Borders, an international not-for-profit organisation working in the field of access to affordable medicines, has cautioned India on the inclusion of intellectual property (IP) in the ongoing negotiations of the … Continue reading

Posted in FTAs, Generic drug, HIV/Aids, Intellectual Property, IP Rights, Right to Health, WTO | Tagged , , , | Leave a comment

Médecins Sans Frontières Warns About IP Inclusion In Asian FTA

August 27,2014 The inclusion of intellectual property in the ongoing negotiations of the Regional Comprehensive Economic Partnership between 16 countries, most of them Asian, is raising concerns about “TRIPS-plus” measures that could jeopardise generic drugs production in India, according to … Continue reading

Posted in ASEAN, FTAs, Generic drug, IP Rights, patent, Right to Health, TRIPS plus | Tagged , , , , , , | Leave a comment

EU nations join forces against ‘exorbitant’ hepatitis C drug

Source: Yahoo News 30 July 2014 Paris (AFP) – France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical … Continue reading

Posted in access to medicines, Drug Pricing, Generic drug, Hepatitis - C, patent, Sofosbuvir | Leave a comment

Getting cured of hepatitis C will cost you your pension

Source: Act Up Paris 28 July 2014 Sovaldi® (sofosbuvir), the new medicine against chronic hepatitis C from American laboratory Gilead, highly increases chances of recovery while also decreasing the side effects that make people stop the cure. A hope of … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Generic drug, Hepatitis - C, IP Rights, patent | Leave a comment

Cost of Treatment against Hepatitis C: The French Government Must Issue a Compulsory License for Sofosbuvir and Seek the Usage of Generics

Source: Act Up Basel 28 July 2014 Act Up-Basel called the French government to learn from the current situation regarding access to new direct-acting antivirals (DAAs) molecules used in the treatment of hepatitis C (HCV), to exercise Article L613 -16 … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Generic drug, Hepatitis - C, patent | Leave a comment

Hepatitis C drugs not reaching poor

Source: Nature 14 July 2014 Treatment guidelines for virus highlight challenge of paying for expensive drugs in low-income countries. The publication last week of the first treatment guidelines for hepatitis C virus (HCV), and the advent of drugs that can … Continue reading

Posted in Drug Pricing, Generic drug, IP Rights, patent | Leave a comment